Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
The approved tenofovir / Viread label lists not only standard nucleoside-class side effects but also – since an update in 2012 – makes mention of diminished bone mineral density (BMD) in the Warnings / Precautions section. Demonstrating that a particular drug affects BMD in patients who are already at an increased risk Continue reading Tenofovir, BMD and Monitoring of Renal Function
For GC antibiotics, the development path looks like a trip down the road less traveled, leading into some uncharted territory. Let’s take Melinta’s statement [1] at face value according to which the single 900 mg dose of delafloxacin failed because of “insufficient efficacy”. So, what then determines efficacy? Delafloxacin’s MIC90 was Continue reading Treating GC in the Face of Dwindling Antibiotic Options – (2)
Vancomycin got a bad reputation since the early 90ies when it became clear that it was slow to provide clinical improvement and microbiologic cure in MRSA patients. It was associated with prolonged bacteremia even when combined with rifampin [1]. And for MSSA, anti-staph penicillins like nafcillin were always the better choice. Then, Continue reading Vancomycin vs TMP/SMX for MRSA – Not the Final Word